Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 short-term investments of $0 is the 10th highest of the 11 companies compared; the peer median is $124.45M.
- Short-term investments amounts to 0.0% of total assets for NVCT, versus a peer median of 43.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $904.56M | -3.8% | +49.1% | 88.0% | |
| Jun 2026 | $402.35M | +11.8% | -13.3% | 54.0% | |
| Mar 2026 | $225.54M | +46.1% | +19.1% | 51.6% | |
| Mar 2026 | $221.17M | -39.0% | -12.1% | 46.8% | |
| Mar 2026 | $139.52M | +94.9% | +5.5% | 68.0% | |
| Mar 2026 | $109.37M | — | +10.3% | 0.1% | |
| Mar 2026 | $87.71M | +923.4% | +42.9% | 40.3% | |
| Mar 2026 | $16.13M | — | — | 7.1% | |
| Mar 2026 | $11.33M | — | — | 11.8% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NVCT) | $124.45M | +29.0% | +10.3% | 43.5% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.